MEF-2A Inhibitors
MEF-2A Inhibitors consist of compounds that, through various mechanisms, can decrease the activity of MEF-2A. These mechanisms include the direct inhibition of kinases that phosphorylate and activate MEF-2A, such as MAPK/ERK with U0126, and CaMKII with KN-93. By inhibiting these kinases, the compounds prevent the phosphorylation and subsequent activation of MEF-2A, thus leading to decreased MEF-2A activity. Other compounds in this class alter the signaling environment that regulates MEF-2A. For instance, Cyclosporin A and H-89 inhibit calcineurin and PKA, respectively, both of which are necessary for the full activation of MEF-2A.
Moreover, compounds such as Valproic Acid and GW9662 work by modifying gene expression and nuclear receptor activity, which can lead to decreased MEF-2A activity. Valproic Acid does this by altering the chromatin state, which can suppress the genes necessary for MEF-2A activation, while GW9662 antagonizes PPARγ, leading to a decrease in MEF-2A activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 is a selective inhibitor of CaMKII, a kinase that phosphorylates MEF-2A. Inhibition of CaMKII activity results in reduced phosphorylation and thus decreased activity of MEF-2A. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits calcineurin, which when active can dephosphorylate and activate MEF-2A. Its inhibition thus prevents MEF-2A activation. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is a potent inhibitor of PKA, which can phosphorylate MEF-2A. Inhibition of PKA leads to reduced MEF-2A phosphorylation and activity. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, while an HDAC inhibitor, can also exert inhibitory effects on MEF-2A by altering the chromatin state and gene expression profiles that could suppress MEF-2A activity. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB 216763 inhibits GSK-3β, which normally phosphorylates MEF-2A. However, in some contexts, GSK-3β activity may be required for MEF-2A activation, so its inhibition could lead to decreased MEF-2A activity. | ||||||
NFAT Inhibitor | 249537-73-3 | sc-507480 | 1 mg | $620.00 | ||
VIVIT peptide disrupts the interaction between NFAT and calcineurin, potentially altering downstream effects on MEF-2A activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can influence multiple downstream signaling pathways, including those that may activate MEF-2A, leading to decreased activity. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 antagonizes PPARγ, possibly counteracting the activation effects on MEF-2A signaling. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone, a glucocorticoid, can suppress various signaling pathways and alter gene expression, potentially downregulating MEF-2A activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK, which may indirectly influence MEF-2A activity by modulating the signaling environment that regulates MEF-2A. | ||||||